Gut microbiome variations during hematopoietic stem cell transplant in severe combined immunodeficiency

J Allergy Clin Immunol. 2015 Jun;135(6):1654-6. doi: 10.1016/j.jaci.2015.01.024. Epub 2015 Mar 11.

Authors

Jonathan P Lane¹, Christopher J Stewart², Stephen P Cummings², Andrew R Gennery³

Affiliations

¹ Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom. Electronic address: jonathan.lane2@ncl.ac.uk.
² Faculty of Health and Life Sciences, University of Northumbria, Newcastle upon Tyne, United Kingdom.
³ Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom.

PMID: 25769913
DOI: 10.1016/j.jaci.2015.01.024

No abstract available

Publication types

Letter

MeSH terms

Anti-Bacterial Agents / therapeutic use
Antifungal Agents / therapeutic use
Antiviral Agents / therapeutic use
Bacterial Infections / drug therapy
Bacterial Infections / immunology
Bacterial Infections / microbiology
Dysbiosis / immunology
Dysbiosis / microbiology*
Feces / microbiology
Female
Gastrointestinal Tract / immunology
Gastrointestinal Tract / microbiology*
Gastrointestinal Tract / virology
Graft vs Host Disease / immunology
Graft vs Host Disease / microbiology*
Graft vs Host Disease / prevention & control
Graft vs Host Disease / virology
Hematopoietic Stem Cell Transplantation*
Humans
Infant
Infant, Newborn
Longitudinal Studies
Male
Microbiota / immunology*
Mycoses / drug therapy
Mycoses / immunology
Mycoses / microbiology
Myeloablative Agonists / therapeutic use
Pilot Projects
Severe Combined Immunodeficiency / immunology
Severe Combined Immunodeficiency / microbiology*
Severe Combined Immunodeficiency / therapy
Severe Combined Immunodeficiency / virology
Transplantation Conditioning
Virus Diseases / drug therapy
Virus Diseases / immunology
Virus Diseases / virology

Substances

Anti-Bacterial Agents
Antifungal Agents
Antiviral Agents
Myeloablative Agonists